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Measles is a highly contagious disease caused by measles virus. Although effective measles 
vaccines have been available since 1963, measles has remained a major public health 
problem. It remains endemic in many countries in Africa and Asia; since 2008, there have 
been large, sustained measles outbreaks across Western Europe and in the USA, as well as 
in sub- Saharan Africa.  Measles mortality has increased every year since 2008. 
 
Between April 2009 and November 2010, South Africa experienced a national measles 
outbreak, with more than 18 000 serologically-confirmed measles cases. The magnitude of 
the outbreak was most likely even greater, as many cases were diagnosed clinically without 
laboratory confirmation.  The outbreak caused high morbidity and considerable mortality.  
Measles outbreaks are common in incompletely vaccinated populations; vaccine coverage in 
South Africa has been inadequate to prevent a measles outbreak.  Outbreaks have also  
historically been associated with higher case fatality ratios than when measles disease is 
contracted by local endemic transmission.  In addition, South Africa has a large population of 
HIV-infected children who are susceptible to measles vaccine failure, and may also be 
susceptible to severe complications of measles disease.   
 
In this thesis, the impact of the 2009-2010 measles outbreak on a single paediatric hospital 
in Cape Town, South Africa is analysed, with description of the numbers of outpatients seen 
with measles, and a detailed analysis of the numbers of measles-related hospital 
admissions.  Particular emphasis is given to the case fatality ratio observed, and the impact 
of age and HIV status on mortality; reasons for the high case fatality are explored. 
 
A literature review explores the impact of HIV-infection on measles-related mortality.  The 
apparent high case fatality described in the early reports of measles / HIV co-infection in the 
USA in the 1980’s and 1990’s is analysed; and the controversies surrounding case fatality of 
measles / HIV co-infection in Africa in the 1990’s and early 2000’s is explored.  The effect of 
anti-retroviral therapy for HIV-infected children with measles, and areas for future research 
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Research Proposal: Impact of measles epidemic at Red Cross Children’s Hospital, 
2009-2010: a retrospective record review 
Principal Investigator: David le Roux, Paediatric infectious disease unit, Red Cross 
Children’s Hospital 
 Email:  David.leRoux@uct.ac.za 
 Cell:   082 372 8449 
 Address:  4th Floor laboratory 
   Institute of Child Health 
   Red Cross Children’s Hospital  
 
Background 
Measles outbreaks are common in incompletely vaccinated populations and are associated 
with high morbidity and high cost.  Measles vaccine coverage in South Africa has previously 
been shown to be inadequate: in a survey in the Western Cape in 2005, only 60% of children 
received a second dose of measles vaccine1.  A correlation between maternal HIV status 
and decreased probability of completing the childhood vaccination schedule has been 
reported from Kwa-Zulu Natal2.  The falling measles vaccination coverage resulted in a large 
pool of non-immune individuals who were susceptible to measles infection.  In addition, HIV-
infected children do not receive adequate protective antibody either transplacentally or 
through breast feeding3.  These combined factors placed South Africa at risk for a measles 
epidemic1.   
 
Since January 2009, the National Institute of Communicable Diseases has reported 17 354 
confirmed cases of measles, 1879 of which occurred in the Western Cape Province4.  About 
half of the cases occurred in children under 5 years.  However the NICD does not provide 
mortality statistics or case fatality ratios, or estimates of disease severity.    Measles case 
fatality ratios in children are reported to range from 0.1% to 30%, depending on the age and 
vaccination status of the child, and whether measles occurred during outbreak or endemic 
transmission5, 6.  An analysis of a subset of measles patients from the 2003-2005 epidemic in 
South Africa, 80% of whom were under 15 years old, revealed a 6.4% case fatality ratio; 
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increased hospitalisation requirements and a trend towards increased mortality.7  However, 
measles severity and outcomes have not been described in children in Cape Town. 
 
For these reasons we decided to investigate the measles patients seen at Red Cross 
Children’s Hospital during the current measles epidemic, and report on the proportion 
needing hospitalisation, the proportion of incompletely vaccinated children, the case fatality 
proportion and the severity of disease associated with other chronic medical conditions. 
 
1) Aim 
To describe the impact of the 2009-2010 measles outbreak on Red Cross Children’s 
Hospital.   
Specific objectives 
1) To report the number of children with measles seen at the hospital from November 
2009 until July 2010; and calculate the cost to the hospital of treating these children. 
2) To describe the presentation and course of measles: age at onset, symptoms, 
disease severity, length of hospital stay, incidence of complications, case fatality. 
3) To explore vaccine issues: how many of the measles cases were incompletely 
vaccinated; vaccine effectiveness in HIV-infected children; and where possible, to 
describe the differences in infant protection if the mother was vaccinated, 
unvaccinated or had had measles infection.     
4) To assess the outcome of measles infection in children with background medical 
disease (cardiac disease, renal disease, HIV infection, chronic pulmonary disease).  
We will review all the deaths associated with measles and describe co-morbidities 
and potential modifiable factors.  
5) To describe the cases of measles pneumonia: risk factors for severe pneumonia; 
severity of disease, ventilation requirements; incidence of secondary bacterial 
infections, courses of antibiotics prescribed; short term outcomes (survival) and long-
term (length of hospital stay, recurrent re-admissions). 
 
2) Methodology 
A) Setting: Red Cross Children’s Hospital 
B) Study design: Retrospective folder review of all patients with proven or suspected 
measles infection from November 2009 to July 2010.  
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Age range: All children seen at the Hospital will be eligible for inclusion the analysis.  
This will include children from a few days old to age 13, with a few teenagers with chronic 
medical conditions. 
Inclusion criteria: Suspected or confirmed measles infection, based on the clinical 
measles definition (Appendix 1).  Will include patients seen in the outpatients department, 
clinics and wards; and patients diagnosed at another institution and transferred to Red Cross 
Children’s Hospital. 
Exclusion criteria:  
Suspected measles patients who were subsequently proven to have another cause for their 
symptoms. 
Staff members, parents and other adults who were formally or informally diagnosed at Red 
Cross Children’s Hospital but were not treated as hospital patients. 
 
D) Recruitment and enrolment  
We will derive a list of names from the hospital notification records, and correlate with 
hospital attendance records. 
 
E) Ethical issues: research procedures and data collection   
The study protocol will be submitted to the Research Ethics Committee of the School of 
Child and Adolescent Health, the administration of Red Cross Children’s Hospital, and 
Human Research Ethics Committee of the University of Cape Town.  The study will be 
undertaken in accordance with the Declaration of Helsinki. 
 
Members of the research team will obtain the hospital records of measles cases; data 
capture sheets will contain names and folder numbers to allow researchers to check 
information from folders after data collection is completed.  Each name/folder number will be 
linked to a study number; study numbers but not names will be entered onto an electronic 
data base for anonymous analysis and reporting.  Quality control will require a random 
selection of 5% of the case notes be reviewed by another member of the research team or 
the principal investigator and accuracy of data entry corroborated. 
 
The principal investigator will analyse the data base. Missing data will be sought in the 
original clinical notes.  We will not seek to make contact with the patients’ families to clarify 
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F) Data safety and monitoring 
As this is a retrospective record review, we do not anticipate that there will be adverse 
events or need for a Data Safety Monitoring Board. 
 
G) Statistical analysis 
The abstracted data set without any personal identifiers will be stored electronically.  Data 
will be collected and recorded into a spreadsheet (Microsoft Excel) and then analysed in 
Stata 10 (Statacorp, College Station, Texas). 
Normally distributed continuous variables will be reported as mean (standard deviation).  
Non-normally distributed continuous variables will be reported as median (interquartile 
range).  Categorical variables will be compared by t test.  Risk ratios and confidence 
intervals will be calculated using standard formulae.  Adjusted odds ratios will be modelled 
using logistic regression.  Count outcomes will be modelled using Poisson regression. 
 
3) Outputs 
The data will be presented at a departmental meeting and submitted for publication.  It will 
form the basis of an MPhil (Paediatric Infectious Diseases) subspecialist qualification for the 
principal investigator. 
 
5) Anticipated gain in scientific knowledge 
The study will contribute to the understanding of measles infection in a high HIV-prevalence 
area.  Identification of risk factors for poor outcomes may affect future case management.  
Results may be generalisable to other hospitals in South Africa and across sub Saharan 
Africa. 
 
6) Description of risks and benefits 
As this is a retrospective record review, we do not anticipate any risk or harm to the study 
patients.  There are no direct benefits to the study participants. 
 
5) Informed consent process 
(Not applicable) 
 
6) Privacy and confidentiality 
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7) Reimbursement for participation 
(Not applicable)  
 
8) Emergency care and insurance for research-related injuries 
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10) Appendices 
1) Measles clinical case definition: 
 A history of fever AND 
 Macuolpapular rash AND 
 A history of ONE of the following: cough OR coryza OR conjunctivitis 















Data collection sheet: Measles epidemic at Red Cross 2009-2010 1 
Data collection sheet (version 3.0) 
 




Study number  
Folder number  
Date of birth  
Gender MALE FEMALE 
Suburb / Township  
 mass (kg) at diagnosis  Z-score: 
 
 
Measles immunisation status 
Patient has RTCH YES NO UNKNOWN 
Measles vaccine – 1st dose given YES NO UNKNOWN 




Patient tested for HIV YES NO UNKNOWN 
HIV Test Date Result 
Rapid   
HIV ELISA   
HIV DNA PCR   
HIV status exposed infected uninfected UNKNOWN 
CD4 completed YES NO UNKNOWN 
CD4 date  
CD4 absolute count  
CD4 percentage  
On ART at time of infection YES NO UNKNOWN 
Date of starting ART  





Location of measles diagnosis and management 
Date of measles diagnosis  
1st hospital location (MOPD/Med Reg/etc.)  
Admission to ward to S11 / SSWE?  
Date of admission to S11 / SSWE  
Subsequent ward movements 
















Data collection sheet: Measles epidemic at Red Cross 2009-2010 2 
Notification and confirmation of diagnosis 
Was child notified? YES NO 
Date of notification  
Was blood sent for IgM studies YES NO 
Measles IgM result  
Rubella IgM result  
 
 
Indication for admission 
Date of admission  
Principal diagnosis  






Underlying medical condition 







Vitamin A administration 
2 doses administered YES NO UNKNOWN 
 
 
Complications during admission and outcome 
Complication associated with admission diagnosis:- 
Respiratory failure Septic shock 
Other (specify):  
ICU admission required YES NO 
Indication for IC  admission: 
Total length of hospital admission:  
Hospital outcome Discharged Died 
Date of discharge / death:  












Data collection sheet: Measles epidemic at Red Cross 2009-2010 3 
Part 2: Admission with Measles pneumonia 
 
Date measles diagnosed: ………………… 
Date admitted to RXH:  
Admitted to ward:  
Transferred in from:  
 














            
            
            
            
            
            
            
            
            
            
            
            
 
 
Only positive culture: 
Date Site  Organism Sensitive to Resistant to Intermediate to 
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     











Data collection sheet: Measles epidemic at Red Cross 2009-2010 4 
  
Antibiotics: 
Name Date started Date completed 
   
   
   
   
   
   
   
   
 
Ventilation requirements 
Date Form of ventilation O2 Requirement Sats 
    
    
    
    
    
    
    
    
 
Blood transfusions 
Date Starting Hb O2 Requirement Volume of 
packed cells 
transfused 
Post TF Hb 
     
     
     
     
 
Chronic illness: Readmissions 
Date Ward Presenting complaint Final diagnosis 
    
    
    
    
    
















MEASLES CASE INVESTIGATION FORM EPID NUMBER: ____________ _ 
Name of person completing fonn: ________________ Signature : ___________ _ 
Sources of Data: Careg iver D Clin ician D Medical records D No data obtained D 
Name of Health Facility attended: ___________ Name of attending clin ician :. _________ _ 
Hea lth Facility street address : _______________________________ _ 
__________________________ ,Contact number: _________ _ 
PATIENT DETAILS 
Fu ll name: _____________________ Gender: M D 
Date of birth: __ 1 __ 1 __ If 008 unknown Age : _ Unit: Days D Wks D Months D 
F D Unknown D 
YrsD ; DOB and Age Unk D 
Street address: ____________________________________ _ 
______ Townl City: _________ Province: _______ Contact Number{s): _____ _ 
CURRENT PRESENTATION 
Presenting symptoms/signs (Tick all applicable Boxes): Rash D Fever D Conjunctivit is 0 Cough D 
Coryza/Rhinitis/runny nose 0 Other (Specify) 
Date of onset of rash: 1 1 I Date of Presentation at the health faci lity: 1 1 
Complications (Tick where applicable): None U Pneumonia U Otitis Media U Diarrhoea U Febrile seizures U 
Laryngotracheobronch itis (Croup) D Corneal Ulceration D Blindness DEncephalitis D 
Clinica l Management: Vitamin A given : Y D N O 
Fina l outcome (Tick where applicable): Patient admitted to Hospita l: Y O N 0 Patient Died: Y D N O 
Specimens Collected (Tick where applicable): Blood/Serum U Urine U Nasopharyngeal/Saliva U 
Dried Blood Spot D Date of specimen collection : 1 1 
MEDICAL AND CONTACT HISTORY 
History of contact with a suspected measles case in the past 7 to 28 days: Y D N D Unknown D 
History of contact with a laboratory confirmed measles case in the past 7 to 28 days: Y D N D Unknown 0 
History of trave l in the past 7 to 28 days: Y D N D ; if yes, name of place or country travelled to 
History of previous visit or adm ission to a healthcare faci lity in the past 7 to 28 days: Y D N D Unknown D ; 
If yes, Name of the Faci lity: Diagnosis at the Faci lity: 
Vaccination Information obta ined from: Road to hea lth card U Self reported U Not obtained U 
Measles vaccination received: If yes, number of doses: 1 U 2 U >2 U 
Y D N D Unknown D Date of last measles vaccine: 1 1 
RESPONSE TO CASE 
Case Notified· Y D N D Unknown D Date of Notification 
Number 
Contacts follow-up Action Taken 
< 5 514 > 15 




Active Case Finding: Y U N Ul Number of suspected measles cases found : None U or specify number 
.. 
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Between 2009 and 2010, South Africa experienced a major measles outbreak, with more than 18 
000 confirmed cases reported to the National Institute of Communicable Diseases.  We studied 
measles admissions during the outbreak at a paediatric hospital in Cape Town, and investigated 
factors associated with mortality. 
Methods 
Children presenting to Red Cross War Memorial Children’s Hospital with measles between 1 
November 2009 and 31 July 2010 were retrospectively identified from notification records and 
hospital admissions data.  Multivariate logistic regression was used to investigate potential risk 
factors for death. 
Results 
In total, 1861 children were diagnosed with measles; 552 (30%) were admitted to hospital.  The 
most common reason for admission was pneumonia (379, 68%) and/or diarrhoea (262, 48%).  
The median age at admission was 7.36 months (interquartile range (IQR) 5.0 to 10.7).  The 
median duration of admission was 4 days (IQR 2-6); total hospital admission time was 3746 days 
(10.3 child-years).  HIV status was known in 404 children (73%): 39/400 (14%) were HIV-
infected.  Eighteen children died (3% of all admissions); 15 of these (83%) were less than 1 year 
old.  In the regression model, HIV-infection (adjusted odds ratio (aOR) 7.55, 95% confidence 
interval (CI) 2.27 – 25.12) and female sex (aOR 3.86, 95% CI 1.26 – 11.84) were associated with 
higher odds of death. 
Conclusions 
There was a large paediatric admission burden during the 2009-2010 measles outbreak in Cape 
Town; young children were predominantly affected.  HIV-infected children had significantly 














Measles vaccination has been very effective in reducing global measles disease burden.  
However, outbreaks can occur when inadequate vaccination coverage allows accumulation of 
sufficient number of susceptible individuals in a population.  The estimated level of population 
immunity needed to prevent measles outbreaks is about 95%.1   South Africa introduced routine 
measles vaccination in 1975, and measles became a notifiable condition in 1979.  In 1995, the 
current 2-dose strategy (routine vaccination at 9 and 18 months) was adopted.  Case-based 
surveillance was introduced in 1998, with all suspected cases having blood or urine tested at the 
National Institute of Communicable Diseases (NICD).2 
 
Accurate coverage of measles vaccination has been difficult to determine.  In 2009, the South 
African Department of Health estimated national coverage with routine measles vaccine to be 
99%, but the World Health Organisation (WHO) and United Nations Children’s Fund (UNICEF) 
coverage estimates were only 65%.3  In 2004, a survey in the Western Cape found 79% of 
children to be “fully vaccinated”.4  In 2005, another study estimated that 93% of children had 
received the first dose of measles vaccine, but only 60% a second dose.5  The authors concluded 
that routine coverage in the Western Cape was too low to prevent a measles outbreak.   
 
The last major outbreak in South Africa occurred in 1992.  In July 2009, a cluster of measles 
cases was detected in Tshwane; in August, the outbreak spread to Johannesburg, and thereafter 
rapidly throughout the rest of the country.  The first case in the Western Cape was confirmed in 
September 2009; there were 14 cases in October and by November the outbreak was well 
established throughout the Cape Town metropole.6  We report the epidemiology of measles cases 




Red Cross War Memorial Children’s Hospital (RCWMCH) is a 290 bed level 3 academic 
hospital in Cape Town.  During the outbreak, children with measles who needed admission were 
stabilised and admitted to the “short stay ward”.  From the short stay ward they were either 















All children diagnosed with measles at RCWMCH between 1 November 2009 and 31 July 2010 
were retrospectively identified from paper notification records, electronic hospital admission 
records, and the ICU database.  Folders were reviewed and patients meeting the World Health 
Organisation (WHO) clinical case definition were included.7  Suspected measles cases who 
tested negative for measles IgM antibodies were excluded.  Data were captured onto a paper 
form and entered into an electronic database.   
 
Final discharge dates and readmission dates were extracted from the city-wide hospital 
admission computer system; this includes all the time spent in any hospital in the city.   
 
Measles case management and prophylaxis 
All children were managed according to written hospital protocols.  In-patient management of 
pneumonia included intravenous ampicillin, gentamicin and cloxacillin.  Vitamin A was dosed 
according to WHO guidelines.7  During the outbreak, all children attending RCWMCH who did 
not have clinical measles were given measles prophylaxis.  Children older than 6 months were 
given a single dose of intramuscular measles vaccine (Rouvax, Sanofi Pasteur, France); children 
under 6 months and children with severe immunosuppression were given an intramuscular dose 
of human immunoglobulin (Intragam, National Bioproducts Institute, South Africa), according to 
the manufacturer’s instructions. 
 
HIV testing  
HIV testing was performed when deemed clinically appropriate by the treating clinicians.   
Children over the age of 18 months were considered HIV-infected if HIV antibodies were 
detected by ELISA (enzyme linked immunosorbent assay) testing.  Results were confirmed on a 
second specimen with a manual ELISA (Enzygnost® Anti-HIV 1/2 Plus, Siemens Healthcare 
Diagnostic Products GmbH, Marburg, Germany).  Children less than 18 months of age were 











Molecular Systems, Branchburg, New Jersey, USA). Positive HIV DNA PCR results were 
confirmed with HIV viral load testing. 
 
Statistical analysis 
For summary statistics, categorical data are expressed as number (percentage); continuous data 
are expressed as median (inter-quartile range, IQR).  Median values were compared with the 
Wilcoxon rank-sum test.  Risk ratios were calculated to compare the proportion of children who 
died or were re-admitted by gender and HIV status.   
 
Factors associated with death were explored with multivariable logistic regression.  We 
evaluated the impact of age, sex, HIV status, immunization status, evidence of vitamin A 
administration, the presence of a “Road to Health Card” and the weight-for-age Z-score 
(calculated from growth charts from Centers for Disease Control and Prevention (CDC)). 
Weight-for-age Z score of less than -2 was considered “moderate underweight for age”; less than 
-3 was considered “severe underweight for age”. Variables associated with the outcome at the 
α=0.1 level were included for multivariable analysis.  Automated backwards and forwards step-
wise model building procedures were used; potential models were compared with Akaike’s 
Information Criteria. Collinearity was assessed with variance inflation factors.  The final model 
chosen was most parsimonious and presented the best AIC value. A sensitivity analysis was done 
to examine the influence of the children with unknown HIV status.  Analyses were done in Stata 
version 10 (Statacorp, College Station, Texas, USA).  All p-values are two-tailed (α=0.05). 
 
Ethics approval was obtained from the Department of Paediatrics and Child Health Departmental 
Research Committee and the University of Cape Town Human Research Ethics Committee, 
HREC-REF number 511/2010.   
 
Results 
From 1 November 2009 till 31 July 2010, 1861 children with measles presented to RCWMCH.   
Outpatients: 
1309 children (70%) were treated as outpatients; most cases presented in March and April 2010 











vaccination status in the hospital notes was poor: of the 565 children eligible for routine measles 
vaccination, only 270 (48%) had vaccination status recorded, and only 68% had vitamin A 
administration documented in the hospital notes, table 1. 
 
Admissions: 
There were 552 hospital admissions; inpatients were significantly younger than children treated 
only as outpatients (median age 7.4 months vs. 8.9 months, Wilcoxon p<0.0001), table 1.  Most 
children (357/552, 65%) were younger than 9 months, the age of routine measles vaccination, fig 
2.  At least 379 (63%) children presented with pneumonia, 262 (47%) with severe diarrhoea and 
163 (30%) with both.  Other reasons for admission included croup (37, 7%), and suspected 
meningitis (2, 0.4%).  Vaccination status was recorded in the hospital notes in 92/195 (47%) 
children older than 9 months; only 40/92 (45%) had had any measles vaccine documented in the 
hospital notes, fig 2.  During the study period, venous blood for serological testing was sent from 
102 children admitted with suspected measles.  Ninety-six (17%) had detectable measles IgM 
antibodies; 4 specimens were invalid or insufficient.  Only 2 children with clinically-suspected 
measles were confirmed measles IgM negative; both children had detectable rubella IgM 
antibodies, and were excluded from this analysis. 
 
Four hundred and four of the admitted children (73%) had known HIV status: 39/404 (10%) 
children were HIV-infected, of whom 20/39 (51%) had been on anti-retroviral therapy (ART) for 
more than 3 months.  All HIV-infected children with severe measles subsequently commenced 
ART.  Only 3/23 (14%) HIV-infected, vaccine-eligible children had documentation of any 
measles vaccination.   
 
Deaths and complications 
Eighteen children died (3% of all admissions); 13 of these (72%) were less than 1 year old.  
Eleven (61%) deaths were due to respiratory failure; other causes included septic shock with 
multi-organ failure (4 children, 22%) and cerebral ischaemia after cardio-respiratory arrest (2 












Seven of 39 (18%) HIV-infected children died, versus 11/365 (3%) known HIV-uninfected 
children.  Case fatality was higher among girls: 5% of girls died versus 1.7% of boys, table 2.  In 
multivariable logistic regression adjusted for age and weight-for-age, HIV infection and gender 
remained strong predictors of mortality, table 3.  Two of the 7 (29%) HIV-infected children who 
died had received ART for at least 3 months.  
 
During the study period, 4 children with complications of measles required tracheostomies (Sr 
Jane Booth, personal communication).  One child was referred with severe croup; three children 
developed upper airway damage following prolonged intubation and ventilation for severe 
pneumonia. All 4 entered the RCWMCH home tracheostomy program, and were discharged 
home within 2 months of their admission.  However they had recurrent re-admissions with 
respiratory infections.  By March 2012, three children had been successfully decannulated, and 
one remains with a tracheostomy.   
 
Length of stay and readmissions 
The median duration of admission was 4 days (IQR 2-6 days).  HIV-infected children were 
admitted for longer (median 6 days, IQR 4-14 days) than HIV-uninfected children (median 3 
days, IQR 2-5 days; Wilcoxon p=0.0007).  
 
Among survivors, boys were more likely to need readmission than girls: 53/287 (18%) of boys 
were readmitted, versus 19/247 (8%) of girls (risk ratio (RR) for readmission 2.40 (95% CI 1.46 
– 3.94, p=0.0003)).  Moderate or severe underweight for age (weight for age Z-score less than -
2) was also strongly associated with readmission: of 531 surviving children with known weight-
for-age, 26/113 (23%) children who were moderately or severely underweight for age were 
readmitted, versus 46/418 (11%) of children who were not underweight for age, RR 2.09 (95% 
1.36 - 3.23, p=0.0009).  HIV-infected children were more likely to be readmitted; 28% (9/32) 
HIV-infected children were readmitted versus 12% (44/354) HIV-uninfected children (RR 2.26, 
95% CI 1.22 - 4.20, p=0.01). 
 
Total primary hospital admission time was 3746 days (10.3 child-years).  Of the 534 surviving 











of all the survivors) were readmitted a third time within 90 days of their first admission.  The 
total time spent in hospital, including the primary admission and subsequent readmissions within 
3 months of discharge, was 4477 days (12.3 child-years).  This constitutes 6.6% of total in-
patient days at RCWMCH during the study period.  
 
Discussion: 
Between April 2009 and November 2010, South Africa experienced a national measles outbreak, 
with 18311 serologically confirmed measles cases. Almost a quarter of these cases were infants 
younger than 9 months.8  The magnitude of the outbreak was most likely even greater, as many 
cases were diagnosed clinically: in our institution, only 96/552 (17%) measles admissions were 
laboratory confirmed.   
 
At RCWMCH, the main burden of disease, both in terms of hospitalisations and mortality, was 
in infants under 1 year; there was an especially high burden in infants younger than 6 months.  
There are several reasons why the very young were so severely affected.  Children become 
susceptible to measles infection once maternally-derived transplacental antibody levels are below 
a protective threshold.  Vaccinated women transfer less antibody than mothers whose immunity 
followed wild-type measles infection.  In Belgium, babies of vaccinated women received 3-times 
lower titre of measles-specific antibodies than babies born to women with immunity due to 
natural measles infection.9  The antibodies are also lost more quickly:  the median time to loss of 
immunity was 0.97 months for babies born to vaccinated women versus 3.78 months for babies 
born to women with previous measles infection.9   
   
In Cape Town, there has been little circulating measles virus since the 1992 outbreak; most 
women of childbearing age have not had natural measles infection.  Since its inception in 1975, 
the coverage of the measles immunization program has been too low; many women have never 
been vaccinated.  Their babies received no measles-specific antibodies, rendering them 
susceptible to measles infection from a very young age.   
 
Case fatality of measles can range from 0.1% in developed countries to 30% in outbreaks among 











status, vaccination status, immune deficiency, vitamin A administration, and access to 
appropriate case management.10   During this outbreak, case fatality among inpatients at 
RCWMCH was 3% (18 deaths out of 552 admissions).  Low weight-for-age Z-score was 
strongly associated with increased mortality, with 35% increased odds of death for every 
standard deviation below the expected weight for age.  Furthermore, among survivors, low 
weight for age Z-score doubled the risk of readmission.  The finding of similar measles incidence 
among boys and girls, but with increased mortality among girls has previously been described,11 
 but the biological mechanism is not well understood. 
 
We observed increased case fatality among inpatients with HIV-infection: these children had an 
18% case fatality ratio, and a 7-fold higher odds of death compared to HIV uninfected children, 
despite half of them being established on anti-retroviral therapy.  This is higher than what has 
previously been reported in areas with high HIV prevalence.  In the 2003-2005 measles outbreak 
in Johannesburg, 14% of known HIV-infected children died; they had a 3.3 times increased risk 
of death compared to HIV-uninfected children.12  In a 6 year study in Zambia, case fatality 
among HIV-infected children was 12%, with 2.5 times increased odds of death compared to 
HIV-uninfected children.13  The higher case fatality in this study may reflect a selection bias for 
disease severity: children admitted to RCWMCH had more severe disease than children treated 
as outpatients or in other facilities in the city.  
 
There are several reasons why HIV-infected children have a more severe clinical course than 
HIV-uninfected children.  HIV-infected children have deficient cellular and humoral immunity, 
as well as impaired innate immune responses.14   Despite commencing ART, HIV-infected 
children had double the risk of re-admission compared to HIV-uninfected children.  This may 
reflect the combined immune-suppressive effect of acute measles infection in an already-
compromised individual.  HIV-infected children have suboptimal responses to measles 
vaccination.   Vaccination, even if not fully protective against measles infection, can attenuate 
severity of disease.10  In HIV-uninfected children, response to measles vaccination is age-
dependant, with better antibody responses in older children: at 9 months, about 90% will develop 
protective antibody levels (interquartile range 82 – 95%); at 12 months, 99% will develop 











However, in HIV-infected children, the response to vaccination does not improve with age.  A 
meta-analysis of 26 studies of vaccine responses in HIV-infected children at different ages 
showed highly variable responses, but no trend towards improved seroconversion among older 
children.  The efficacy of a single dose of measles vaccine whether given at 6, 9 or 12 months 
was about 59% (95% CI 46-71%).15  These studies only reported attainment of protective 
antibody levels, and did not take into account T cell-mediated immunity, effectiveness of 
protection from clinical disease, or the effect of commencing ART.  However, in a retrospective 
analysis of the 2003-2005 measles outbreak in Johannesburg, effectiveness of measles vaccine in 
preventing clinical disease among HIV-infected children was calculated at 63%.12  Infants born 
to HIV-infected mothers who are themselves uninfected (HIV-exposed, but uninfected) also have 
increased susceptibility to measles infection. HIV-exposed infants have lower levels of maternal 
antibody, and protective antibody is lost earlier than in HIV unexposed infants.16 
  
Among the children admitted to hospital, there were 69 possible “vaccine failures” – children 
with record of at least 1 dose of measles vaccine, who developed severe clinical disease requiring 
admission.  There are a number of possible explanations for these vaccine failures.  When 
vaccinations were documented, the admitting clinician noted whether measles vaccine had been 
given, but not the date of administration.  It was not possible to determine retrospectively the age 
at vaccination or time from vaccination till clinical disease.  All children over 6 months of age 
received measles vaccine if they attended hospital, and there were two nationwide mass 
vaccination campaigns (12-23 April and 24-28 May 2010).  However, vaccination of young 
children is known to be less effective than of children over 1 year of age.7  Some children may 
already have been infected with measles, but were vaccinated while in the incubation period.  All 
children under 6 months of age seen at the hospital who did not have measles were given 
measles immune globulin.  If these children were subsequently vaccinated, the immune globulin 
could impair vaccine effectiveness for up to 9 months.17  If they developed clinical measles 
despite having had a vaccine dose recorded in their Road to Health Card, they would be 
considered vaccine failures. 
 
There are several limitations to this study.  As the data was captured retrospectively from clinical 











were not able to explore many of the possible vaccine failures.  Weight-for-height is a better 
marker of malnutrition than weight-for-age, but very few children had their height measured.  
Some children with low weight-for-age Z-scores may have been born pre-term; it may be a 
marker of low birth weight or pre-term delivery, not adequacy of post-natal nutrition.  Most of 
the clinically-diagnosed cases were not laboratory-confirmed.  Dermatologists reviewing 
children admitted with severe measles at another hospital in Cape Town during the epidemic 
found a high correlation between clinically-suspected measles and laboratory-confirmed measles. 
However, this may not apply to clinical diagnosis of mild disease in outpatients.18 
    
In conclusion, the 2009-2010 measles outbreak was associated with a large case load, and high 
morbidity and mortality at Red Cross War Memorial Children’s Hospital.  Over 65% of the 
admissions were for children aged less than 9 months.  Measles is a preventable disease, given 
sufficient political will for the interruption of measles transmission.    We urgently need to 
improve vaccine coverage, and target supplementary immunization activities to under-serviced 
communities.  HIV-infected children had significantly higher case fatality and risk of re-
admission.  Prevention of vertical transmission of HIV is a national priority; coverage of these 
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Addendum for MPhil Thesis (Not included in published manuscript) 
 
1) Calculation of total costs to the hospital of the measles epidemic was one of the 
research objectives; this was omitted from the published manuscript due to word-
count limits.  Total hospital costs for the study period were obtained from the 
hospital finance department.  The average cost per day for an in-patient was 
calculated at about R2912 per day.  The approximate cost to the hospital of all 
the measles admissions was R14,606,596.  The 1309 measles cases who were 
seen as outpatients constituted 0.97% of all outpatient visits over the study 
period; the cost to the hospital was calculated as R1,311,876.  The calculated 
costs of the outpatient visits is an under-estimate, as each child with measles 
was counted once irrespective of how many times they attended as outpatients.  
The total cost to the hospital of inpatient days and outpatient visits was estimated 
at R15,918,473.   
2) Analysis of measles pneumonia was initially one of the research objectives.  
However, it soon emerged that one of the ICU fellows was analysing the measles 
pneumonia cases who were admitted to the Red Cross War Memorial Children’s 
Hospital ICU.   As her project included risk factors, ventilatory requirements and 
complications of measles pneumonia in ICU, in my analysis I did not explore the 




















Age: months: median (IQR) 8.9 (6.1 – 30.4)  
 
7.36 (5.0  – 
10.7) 
8.3 (5.7 – 21.9) 
 
Eligible for routine vaccination (>9 
months) 
 Vaccination status documented in 
hospital notes 
 At least 1 dose of measles vaccine 
















Vitamin A:  
   Given 






















  Known HIV status 
      HIV uninfected    
      HIV infected 
           On ART  
  
404/552 (73%)  




Weight for age Z score 
(IQR) 
 -0.76  
(-1.73 – 0.24) 
 
Road to Health Card seen 
  Yes 
  No 



















Confirmed cases (IgM)  96/552 (17%)  










Number readmitted (<30 days)  72/534 (13%)  
 
IQR: Inter quartile range 














Table 2: Deaths by sex, age, HIV status and vaccination status 
 
 Total deaths / Total children  
(%) 
Age 
  < 9months 





  Boys 
  Girls  
 
5/292 (1.7%)  
13/260 (5.0%) 
HIV status 
  HIV-infected 
  HIV uninfected 






  Any measles vaccination 
  Never vaccinated 


















Table 3: Odds ratios (unadjusted and adjusted) of death 
 
 Unadjusted OR (95% 
CI) 
 p value Adjusted OR (95% 
CI) 
 p value 
Weight for age Z-score 0.70 (0.56 – 0.88) 0.002 0.65 (0.47 – 0.91) 0.012 
Sex:  
  Boys 
  Girls 
 
1 











  HIV uninfected 
  HIV infected 
 
1 








































































At least 1 dose measles
vaccine















Measles case fatality comparing HIV-infected to HIV-uninfected children in pre- and 
post-anti-retroviral therapy eras: a literature review 
Introduction 
Measles is a highly contagious disease caused by measles virus.  Effective measles 
vaccines, in use since 1963, have led to massive decreases in global measles morbidity and 
mortality.1  However, despite improvements in measles vaccine coverage, measles has 
remained a major public health problem.  Globally, nearly 120 000 children under 5 years 
died of measles in 2008; measles caused 1% of child deaths under 5 years in Africa and 3% 
of child deaths under 5 years in Asia.2  Since 2008, there have been large, sustained 
measles outbreaks across Western Europe and in the USA, as well as large outbreaks in 
sub-Saharan Africa; measles mortality has increased every year since 2008.3 
Measles disease has a highly variable case fatality ratio (CFR).  Although measles deaths in 
industrialised countries are rare, the World Health Organisation estimates case fatality ratios 
in developing countries to be between 5 and 10%.1  Other factors which are known to affect 
case fatality are age, intensity of exposure to infection (which is primarily associated with 
over-crowding), measles immunization status, malnutrition, vitamin A deficiency and immune 
deficiency.  Due to clustering of risk factors, measles outbreaks among refugee populations 
can have case fatality of up to 30%.4 
Higher case fatality ratios, along with increased severity of disease, were described among 
HIV/measles co-infected adults and children in the USA during the pre-anti-retroviral therapy 
(ART) era.5  However, some of the early reports of case fatality ratios of measles in HIV-
infected children in sub-Saharan Africa provided contradictory results, and it was 
hypothesized that the impact of HIV infection on measles case fatality was less marked in 
African children  than what was observed in the USA.5, 6  The relative risk of death from 
measles in an HIV-infected child compared to an HIV-uninfected child has not been 
quantified. 
Since the advent and large-scale roll-out of ART, much attention has been given to the 
safety and effectiveness of measles vaccination in HIV-infected children.  A large meta-
analysis reported that measles vaccination in HIV-infected children is safe and rarely 
associated with adverse complications.  However, vaccination in HIV-infected children is less 
















susceptible to measles vaccine failure.7  The potential benefits of measles re-vaccination 
once immune reconstitution has occurred is currently being explored.8  The independent 
effect of ART on measles case fatality ratio without revaccination has not been examined.   
Objectives 
This literature review addresses the case-fatality ratio of measles infection in HIV-infected 
children compared to HIV-uninfected children; and examines the evidence for reduction of 
measles-specific case-fatality ratio in HIV-infected children who are receiving ART.    
Methods  
Information sources and search strategy 
The literature search was limited to English-language articles in MEDLINE 
(www.ncbi.nlm.nih.gov) and was performed on 15 January 2013.  Results were limited to 
humans.  The following search string was used: 
(measles hiv) AND ((child OR children OR pediatric)) AND ("death" OR "case fatality" OR 
"mortality"))  
Eligibility criteria 
“Children” were defined as those less than 18 years old.  Review articles or articles 
presenting a modelling exercise which did not present new cases were excluded.   Articles 
that did not report any deaths, any HIV-infected children, or where it was specifically 
mentioned that no measles cases had occurred were also excluded.  Letters, comments, 
guidelines and treatment protocols were excluded.  When articles reported sub-analyses or 
interim analyses of a larger cohort, only one of the articles reporting results from that cohort 
was used.  Individual case reports of atypical measles disease or unusual severity of 
disease in a single HIV-infected child were provisionally included; once it could be 
established that the subject of the original case report was subsequently included in a case 
series of HIV-infected children, then the case series was included and the case report 
excluded.  For each case series, the total number of children was ascertained, as well as the 
number of new cases for analysis.  Where the same patients were described in more than 1 
case series, only the original description was included; subsequent references to the same 
















no deaths due to measles, or if the case fatality ratio of HIV-infected children was not 
presented separately from the overall case fatality ratio, then the article was excluded.  
Reference lists of all full text articles were reviewed and screened for other possible articles. 
Conference abstracts, grey literature and unpublished reports were not included.  A single 
reviewer evaluated all retrieved articles by title, abstract or full text.   
Data collection and analysis 
As the intention was to get a broad overview of the topic, a range of article formats were 
accepted.  Data was captured onto structured data capture forms.  Information on study 
type, sample size, outcomes and loss to follow-up were noted.  Case fatality ratios (CFR) 
were calculated manually; relative risks (RR) and 95% confidence intervals (95% CI) were 
calculated for case fatality using the “csi” Stata command (Statacorp, College Station, TX, 
USA).  As the articles reported data from very different clinical scenarios, and included case 
series, cohort studies and opportunistic samples of hospital attenders or hospital 
admissions, it was difficult to exclude heterogeneity; no attempt was made to perform meta-
analysis.   
Quality criteria and case definitions 
Unless the original article distinguished probable from confirmed measles infection, no 
distinction was made in this analysis.  As serological diagnosis in HIV-infected children is 
often complicated by lack of robust immune response,9  all measles cases that were 
included by the original authors were included, even if measles antibodies were not 
detected.    
As far as possible, diagnosis of HIV infection was based on either virological evidence of HIV 
infection (DNA PCR or RNA viral load) or the persistent presence of HIV antibodies.    For 
most studies, the cut-off age for persistent antibody presence could be set at 18 months; 
where the case fatality data was not stratified at 18 months, but the authors had presented 
grouped data at 15 months, then the author’s cut-off of 15 months was used.  Children below 
this age who had detectable HIV antibodies but without virological confirmation of infection 
were considered “Indeterminate HIV status”.  In these situations, the numbers of children 
with indeterminate status and the numbers who were untested were added together and 
regarded as “Unknown HIV status”.  Case fatality ratios for the confirmed HIV-infected and 

















Description of included studies 
The search strategy yielded 89 potentially relevant articles, figure 1.  Most ineligible articles 
were excluded on the basis of information contained in the title or abstract.  Twenty-nine 
articles were retrieved and reviewed in full text.  Eleven articles from the Medline search 
were included for analysis; only 1 additional article was identified from the reference lists.   
The search strategy yielded 3 case series of HIV-infected children in the USA in the 1980’s 
and 1990’s, and 2 literature reviews of case reports and case series. These five papers 
report 6 deaths among the 19 HIV-infected children identified, case fatality ratio (CFR) 33%, 
table 1. 
Three retrospective reviews of measles cases in African children were identified. Two were 
hospital based, and recorded HIV / measles case fatality ratio among inpatients;10, 11 the 
other was community-based, and identified ambulatory and hospitalised measles cases from 
public health notification records,12 table 2.  Three prospective studies of children 
hospitalised with measles were identified: two in  Zambia13, 14 and one in Zaire.6   Another 
article that was identified in the search strategy9 was excluded from the final selection for 
analysis as it contained interim data on the all the patients included in a later report.13 
Only one description of a birth cohort was identified that presented measles case fatality 
ratio stratified by HIV status.15  This study was part of the long term follow-up of a perinatal 
HIV transmission study in Nairobi, Kenya; 109 infants born to HIV-infected women and 194 
control infants (born to HIV-uninfected women) were enrolled and followed for up to 3 years.  
However, with only 26 measles cases and 2 measles-related deaths, the comparison of case 
fatality is inconclusive.  One of the deaths occurred in an HIV-exposed child who had clinical 
stigmata of HIV disease but died before confirmatory testing; the child is listed in table 2 as 
being of “indeterminate status”.   
In all 7 reports of HIV-infected children in Africa it was possible to calculate the CFR of HIV / 
measles co-infection; it ranged from 0%15to 57%6 with a median of 18%.   However, due to 
heterogeneity of data and study designs it was not possible to calculate a meaningful 
summary statistic of the CFR across the studies.  From 5 of the reports it was possible to 
calculate a relative risk of death due to measles comparing HIV-infected and HIV-uninfected 
















had reported adjusted odds ratios acquired from multivariable logistic regression; these 
ranged from 2.5 times to 7.55 times increased odds of death.  
Only 1 study reported whether or not the HIV-infected children were receiving anti-retroviral 
therapy.11  Twenty of the 39 HIV-infected children (51%) had received ART for more than 3 
months at the time of measles diagnosis; 2 out of 7 (29%) of HIV-infected children who died 
were receiving ART.  Thus the CFR of children receiving ART was 2 of 20 (10%) versus 5 of 
19 (26%) for children not receiving ART.  This suggests a 38% reduction in the risk of death 
for children established on ART for more than 3 months, although the results are not 
statistically significant due to low sample size (RR 0.38, 95% CI 0.08 – 1.73).   
Discussion 
This literature review synthesises and organises the published evidence about the case 
fatality ratio in HIV-infected children with measles.   Early case rep rts from the USA during 
the 1980’s and 1990’s described very high case fatality ratios of up to 50%.5, 16-19  These 
reports contributed to the early understanding of the clinical impact of paediatric HIV 
disease, and illustrated the potential severity of measles / HIV co-infection.  However, as the 
prevalence of paediatric HIV was too low in the USA, and measles cases were limited to 
outbreak scenarios it was not possible to accurately estimate the true case fatality at a 
population level.  
Some authors suggested that the effect of HIV infection on measles case fatality in Africa 
may not be as pronounced as in the West.5, 13 In 1999 Moss et al reported high measles 
case fatality ratios in the USA, and a high proportion of HIV-infections among children who 
died of measles in Puerto Rico. However the same paper stated that “the data comparing 
the severity of measles in HIV-infected and uninfected children in developing countries are 
less consistent”.5  The two studies that were quoted are included in this analysis.6, 14 Sension 
and colleagues described 314 children with measles under the age of 5 years admitted to 2 
hospitals in Kinshasa, Zaire.  They reported that “no difference in the overall case fatality 
between HIV-seropositive and seronegative children was observed.”6   In the original 
analysis, all the HIV-exposed but uninfected infants and young children (who still had 
detectable maternal antibodies) were analysed together with the older children with 
confirmed HIV infection.  When the case fatality of children under 15 months old 
(indeterminate HIV status) was calculated separately from the case fatality of children older 
















children had a statistically significant 2-fold increased relative risk of death compared to the 
confirmed uninfected children (RR 2.03, 95% CI 1.04 – 3.96)  
The second article14 that was quoted by Moss in 1999 shows an even stronger effect of HIV-
infection on case fatality: in this study, HIV-infected children had a highly significant 3-fold 
increased relative risk of death compared to confirmed HIV-uninfected children (RR 3.28, 
95% CI 3.46 – 12.06).  In this paper, the authors placed emphasis on the gender difference 
in measles mortality, and how this is influenced by vaccination.  The data was presented 
stratified by age, gender, HIV antibody status and vaccination status.  The 356 patients were 
divided into 24 mutually-exclusive categories.  This complex means of presenting the data 
allows for multiple comparisons, but did not accentuate the independent effect of HIV-
infection across all age groups, gender and vaccination groups. 
The largest study to prospectively investigate hospitalised measles case fatality analysed 
1227 children with confirmed measles and known HIV status who were admitted at the 
University Teaching Hospital in Lusaka, Zambia in the five and half years between January 
1998 and July 2003.13 In this study, misclassification was minimised by confirming all 
suspected measles cases serologically, and confirming HIV status on all participants with 
RNA viral load assessment.   There were 189 deaths, overall CFR 5.5%.  A significant 2.5 
times increased odds of death for HIV-infected children compared to uninfected children was 
reported, after adjusting for the effect of age, sex, vaccination status, maternal education, 
and the presence of a desquamating rash.  It is interesting that when the interim results of 
this study were analysed after two and half years of recruitment (from January 1998 until 
October 2000)9 there had been 23 deaths among 546 children with known HIV status (CFR 
4.2%)  However at this stage, there was no statistical difference between HIV-infected (CFR 
5.4%) and uninfected (CFR 4.0%) children, (RR 1.35, 95% CI 0.52 – 3.55).  The authors did 
not discuss the surprising increase in CFR among the HIV-infected children during the latter 
three years.  Of the 681 children enrolled after October 2000, there were 45 deaths (CFR 
6.6%); but the deaths were disproportionately distributed among HIV-infected children: 18 of 
the 96 HIV-infected children enrolled after October 2000 died (CFR 19 %) compared to 27 of 
















Potential for bias and confounding 
Disease severity 
In the early days of the HIV epidemic, only the most severe or dramatic measles cases 
would have been published as case reports, whereas mild disease or typical disease 
progression would not have attracted the same attention.  Therefore early case report-based 
CFRs of up to 50% are probably overestimations of the true CFRs at that time, as the 
denominator would be under-estimated as mild cases would not be included.  The same 
would apply to the calculated overall case fatality ratio of 33% among all the published cases 
as summarised in table 1.5, 16-18 
In the most recent South African measles outbreak, the children with severe disease were 
more likely to be intensively investigated: every child who died or was admitted to ICU was 
tested for HIV, but 27% of the hospitalised children with mild / moderate disease were not 
tested.11  Thus the case fatality ratio of 18% of HIV-infected inpatients may be an 
overestimate, as some of the untested children may have been HIV-infected, resulting in an 
underestimated denominator.  Similarly, the 50% HIV-associated case fatality seen in the 
isolation and infectious disease wards in  Durban hospitals10 contrasts starkly with the 
overall measles case fatality of 7.8%, and reflects that HIV was probably under-diagnosed in 
the less severe measles cases  (only 98 of 11 077 (0.009%) of children were tested for HIV). 
Study population 
 Hospital-based studies of inpatients only describe the most severe end of the clinical 
spectrum of measles disease.  It is not possible to accurately estimate the overall case 
fatality of measles /HIV co-infection without knowing the numbers of children who had mild 
disease and were never hospitalised.  As discussed above, the birth cohort from the Kenyan 
perinatal HIV transmission study gives a good idea of the population-based incidence of 
measles, but had too few measles cases for meaningful interpretation.15  In Cape Town 
between 2009 and 2010, less than 30% of the children diagnosed with measles were 
hospitalised.11  The case fatality reported for the hospitalised cases (18/552, 3.0%) goes 
down to less than 1% if ambulatory patients are included in the denominator; however HIV 
status was not available for the outpatients.  The only study that attempted to calculate 
measles/HIV CFR in a community-based setting at a district or regional level was the case-
















South Africa.12  Measles cases notified from July 2004 were traced, but the field 
assessments and home visits of this study were performed in May and June 2005, up to 11 
months after the notification.  Only 31% of notified measles cases or their families could be 
found and interviewed.   This is the only estimate available of community-based measles / 
HIV case fatality; however with so much missing data, possible differential loss to follow-up 
and the potential for inaccurate recall, both selection and information biases may affect the 
reliability of the estimate. 
Measles case definition 
The clinical definition of measles infection consistently included fever, cough, coryza and 
conjunctivitis.  The duration of the rash that was required to meet the clinical case definition 
for a particular study ranged from 3 to 7 days; one study included the distribution of the rash 
(starting on the head and shoulders, then spreading distally over the next 48 hours.15  As the 
exanthem of measles in HIV-infected children can be variable or absent, it is possible that 
some HIV-infected children with mild disease may not have been included in the case 
definition.  If mild cases were excluded from the denominator, then the case fatality 
proportion may be falsely elevated. In addition, HIV-infected children may present with 
severe measles pneumonitis without skin rash; these children would be diagnosed with 
severe community-acquired pneumonia unless measles-specific viral studies were 
requested.  Thus, some HIV-infected children with severe measles disease may not be 
included in the numerator as the measles infection was not clinically obvious. 
Timing of measles-related deaths 
Most studies did not specify when death had to occur to be considered “measles related”; 
the stated range was from 14 days after the onset of the rash14 to within 30 days after first 
hospitalisation.11  As measles infection causes profound immune suppression, can cause 
malnutrition and may involve hospitalisation and the risk of other nosocomial infections, it is 
possible that an illness episode that begins with measles infection may ultimately prove fatal, 
but the process could take several weeks.  It is possible that more children died after 
measles infection than are captured in this data, and that the calculated case fatality ratios 
















Publication / language bias 
As only English titles were reviewed, it is possible that case reports or case series from 
South America or Central and West Africa may not have been included.  It is striking that no 
reports from Asia were detected in the Medline search string or in the reference lists of the 
included articles.  Thus the included cases only reflect the cases identified in Africa and the 
USA.  However, sub-Saharan Africa has the largest total number of paediatric HIV cases, 
and the articles in this review may be an appropriate reflection of the global measles / HIV 
disease burden. 
Conclusion 
This literature review has organized the published literature regarding the case fatality of 
measles disease in HIV-infected children over 25 years and across 2 continents.  There 
were not enough good quality population-based studies to accurately determine measles / 
HIV case fatality among ambulatory children; and the absolute risk of death among 
hospitalized children had a wide range depending on the site, time period and study 
methodology used.  However, when the relative risk of death of HIV-infected children was 
compared to HIV-uninfected children, HIV-infected children had consistently higher case 
fatality across all the studies.  There was no evidence that HIV infection in African children 
has less impact on measles severity than was observed in the USA in the late 1980’s and 
early 1990’s.   There is good immunological reason to suppose that ART would decrease 
measles-specific CFR.  However, a  this has only been reported in 1 small retrospective 
cohort, there is not yet strong statistical evidence of the impact of ART on this specific 
aspect of overall child survival.  There is need for ongoing measles surveillance in Africa, 
and vigilance from paediatric ART researchers to identify further risk factors for measles 
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Total articles (n=90) 
 
Search string 
(measles hiv) AND ((child OR children OR pediatric)) AND ("death" OR "case fatality" OR "mortality")) 
   
 
 
Articles reviewed in full text (n=29) 
 
Articles included in review 
(n=12) 
Articles excluded: 
Case fatality ratio not reported (n=6) 
No measles cases / measles deaths (n=4) 
Review article (n=2) 
Measles case fatality modelling – no new cases reported 
(n=3)  
Sub-analysis of included cohort (n=2) 
 
Reference list searches 
1 Article found (n=1) 
 
Articles excluded on review  of title / abstract:  
Review article, no new cases (n=32) 
No comparison made of HIV infected and uninfected (n=16) 
No deaths reported (n=9) 
No HIV infected children (n=2) 

















Table 1.Description of case series of HIV-infected children 
 
 MMWR: Mortality and Morbidity Weekly Report 













Case series of HIV-infected 
children with measles  
 
USA, 1986-87 6  4 (subsequently included in Krasinski) 2 1 / 2 (50%) 
Krasinski, 
1989 
Case series of HIV-infected 





5  1 ( A young child < 9 months with 
indeterminate HIV status subsequently 
confirmed uninfected) 




Case series of HIV-infected 
children with measles 
USA, 1990-
1991 
6  (None excluded) 6 3/6 (50%) 
Kaplan, 
1992 
Literature review of case reports 
and case  series of HIV-infected 
children with measles 
 
USA;  time 
period not 
stated 
27  24 (1 was over 18 years old; 16 were included 
in Sension (1989); 5 included in Krasinski 
(1989); 2 included in MMWR) 
3  1/3 (33%) 
Moss, 
1999 
Literature review of case reports 
and case series of HIV-infected 
children with measles 
 
USA;  time 
period not 
stated 
19  15 (6 included in Palumbo; 5 included in 
Krasinski (1989); 2 included in MMWR, 2 
included in Kaplan) 
4 0/4  


































































disease units at 
Clairwood  or 
King Edward VIII 
Hospitals 
11 077 10 10 979 /  
11 077 
(99.1%)  



















measles at a 
teaching 




















0/148 7/39 (18%) 4.69  
(2.41 – 9.14)  
 
Adjusted odds 
ratio: 7.55 (2.27 – 
25.12) 
McMorrow








All children + 
adults  with 
confirmed 
measles traced; 







<5 years: 14 






Not reported 2/14 
(14%) 































































































All children with 
measles 






measles / HIV 
status 
189 / 1227  
(7.2%) 
 





(1.74 – 4.53)  
 
Adjusted odds 













admitted to 2 
hospitals in 
Kinshasa 
314  7 
seropositive 
















2.03 (1.04 – 3.96) 
 












from birth for 3 
years 
26 2 5 2 1 / 14 
(7.1%) 
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    FACULTY OF HEALTH SCIENCES   Human Research Ethics Committee 
 
FHS 013: Measles at Red Cross Children’s Hospital: a record review (D le Roux) 
 
1 
Form FHS013: New protocol application form – section A 
 
1. General information 
Protocol title Impact of measles epidemic at Red Cross Children’s Hospital, 2009-2010: a 
retrospective record review 
 
2. Investigator(s) profile 
UCT’s principal investigator (PI) 
Title, first name, surname Dr David le Roux 
Department/Division Paediatric infectious disease unit 
Phone 082 372 8449 
Email address David.leRoux@uct.ac.za 
Office mailing address 4th Floor Laboratory, ICH building, Red Cross Children’s Hospital 





  No Registration # MP 0506362 
 
Note:  
• If a non-medically trained PI is overseeing research which involves medical procedures, the application 
must include a medical doctor registered with the HPCSA as a co-investigator. 
• The research must have a UCT-based principal investigator, co-investigator or supervisor. 
 
2.2 Co-investigator(s) 
Title, first name, surname Department/Division E-mail 
   
   
   
   
   
   
   
   
   
   
 
 
2.3 How many of the following does the PI currently oversee?  
(Total number for all research projects) 
Open research studies 0 Sites (excluding this application) 0 
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2.4 What is the PI’s role in authoring this protocol?  (tick √) 
Primary author √ 
Collaborator  
None (developed by sponsors)  
 
2.5 Are there any publication restrictions on the research? 
√  No   Yes 
If yes, please describe and justify: 
 
 
3. Protocol profile 
3.1 Has this protocol been submitted to another Human Research Ethics Committee? (tick √) 
√  No   Yes 
If yes, please 
complete: 






3.2 To your knowledge, has this protocol been rejected by another HREC? (tick √) 
√  No   Don’t know   Yes 
If yes, please provide the reasons: 
 
 
3.3 Is this application similar or related to research previously approved by this Committee? (e.g. a 
sub-study, follow-up study, earlier phase trial)? (tick √) 
√  No   Yes 
If yes, please 
complete: 
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3.4 Is this protocol for degree purposes? (tick √) 
  No  √  Yes 
If yes, please specify: 
Type of degree M Phil (Paediatric infectious disease) 
Student’s name and e-mail Dr David le Roux David.leRoux@uct.ac.za 
 Supervisor’s name and e-
mail 
Prof Brian Eley 
Brian.Eley@uct.ac.za 
Department and University School of Child and Adolescent Heath, UCT 
 
3.5 Does this protocol comply with the Helsinki Declaration of 2008? (tick √) 
  No √  Yes 
If no, please explain with full justification 
 
 
3.6 Does the protocol provide insurance for research-related adverse events (tick √) 
√  NA (e.g. minimal risk research, medical record review)    No   Yes 
If yes, please describe: 
ABPI-compliant corporate insurance policy  
UCT’s no-fault insurance policy  
Other. Please specify  
 
 
3.7 Does the protocol comply with UCT’s intellectual property rights policy? (tick √) 
 √ Yes   No 
If no, please justify 
 
 
4. Funding and grant information 
4.1 Funding source (tick √ at least one) 
No funding/sponsor  skip to Q. 5 √ 
Agency-funded (e.g. MRC, NRF, Wellcome Trust, Bill and Melinda Gates Foundation)  
US Federal funding (e.g. NIH, CDC)  
UCT (e.g. departmental funding)  
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4.2 Ethics review levy (Industry-sponsored research only) 
For invoicing purposes, please provide: 
Sponsor’s name  
Contact person  
Address  
Telephone number  
 
Note: the HREC does not have the authority to waiver the ethics review levy. If a waiver is required, please 
contact Mr Salie Nassiep, the Research Management Accountant in the Faculty of Health Sciences (021 406 
6409). 
 
4.3 What is the total sponsorship/funding for this protocol?  
 




4.5 Where applicable, has the PI negotiated an agreement with the hospital or other health or 
laboratory services to cover the costs of interventions/ procedures/ investigations performed solely 
for research purposes? (e.g. extra MRIs, CT scans, diagnostic tests, prolonged hospitalisation, use of non-research staff to 
collect research-related data or perform research-related procedures) (tick √) 
  NA    Yes   No 






Note: a summary budget must be attached in the appendices. 
 
5. Characteristics of the protocol 
5.1 Category of research 
Please select an appropriate category for your protocol. If the protocol falls in more than one category, 
please designate a primary and secondary category by entering a ‘1’ and a ‘2’. 
 Medical intervention/ clinical trial (e.g. drugs, devices, innovations)  
Behavioural/ psychosocial interventions (e.g. comparison of counselling programmes)  
Epidemiology/ observational study (e.g. survey, prevalence, case control, cohort studies)  
Quality improvement  
Testing new technologies  
Medical record review, audit √ 
Establishment of a specimen repository, medical data base/ registry  
Clinical laboratory studies  
Qualitative research (e.g. focus groups, in-depth interviewing, ethnography)  
Pilot study  
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5.2 Category of participants   Adults √  Minors (<18 years). Please specify age range: 0-16 yr  
 
5.3 Estimated number of participants About 1000 records 
 




5.5 Location(s) of the study: 
Red Cross Children’s Hospital 
 
 
5.6 Will non-English speaking participants be enrolled in the study? (tick √) 
 √ NA   No   Yes 
 
If yes, please tick √ what measures will be used to promote participants’ and families’ understanding: 
Written translation of consent/ assent forms into Afrikaans  
Written translation of consent/ assent forms into Xhosa  
Use of trained translator(s)/ interpreter(s)  
Other. Please specify below and describe how the investigators intend to explain the study to potential 







5.7 What measures will be taken to protect confidentiality (tick √) 
Paper-based records will be kept in a secure location and only accessible to personnel 
involved in the study 
√ 
Computer-based records will only be available to personnel involved in the study through the 
use of access privileges and passwords 
√ 
Personnel will be required to sign statement  agreeing to protect the security and 
confidentiality of identifiable information 
√ 
Personal identifiers will be removed from research-related information √ 
Encryption NA 
Audio and/ or video recordings will be transcribed and then destroyed to eliminate 
identification of participants 
NA 
Use of pseudonyms NA 
Participants in focus groups will be advised that confidentiality cannot be assured NA 
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6. Clinical trials 
This section must be completed only if the research involves a clinical trial of drugs/ medicines, herbal, 
complementary or indigenous therapies; therapeutic devices; an innovative therapy or intervention; off-label 
use or a departure from standard treatment or care. 
The SA GCP Guidelines (2006) define a clinical trial as any investigation in human participants intended to discover or verify the 
clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse 
reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational 
product(s) with the objective of ascertaining its safety and/or efficacy. 
Is this protocol a clinical trial (tick √):   Yes  √ No  (If no, please go to Q.7) 
 
6.1 Is the product registered with the Medicines     
Control Council (MCC)? (tick √) 
  Yes   No 
If yes, please provide the registration number  




 Application submitted 
If registered, will the product be studied for an indication different to that approved 
in the SA package insert? 
  Yes   No 
If registered, will the product be studied using a dose different to that approved in 
the SA package insert? 
  Yes   No 
If registered, will the product be studied using a formulation different to that 
approved in the SA package insert? 
  Yes   No 
If registered, will the product be studied using a route of administration different to 
that approved in the SA package insert? 
  Yes   No 
 
Note:  If yes to any of the above, MCC approval is required. 
 
6.2 Does the study involve an FDA-monitored product 
(drug, device or biological)? (tick √) 
  Yes   No 
 
6.3 Is this trial registered with the South African 
Clinical Trial Register? 
 
  Yes   No   
If yes, please provide the registration number  
If no   Application submitted 
 
6.4 Does this trial comply with the Guidelines for 
Good Practice in the Conduct of Clinical Trials with 
Human Participants in South Africa, 2nd Edition, 
2006? (tick √): 
 
  Yes   No   
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6.5 Is the PI covered by professional liability 
insurance? (tick √): 
  Yes   No   
If yes, please provide Medical Protection number  
 
6.6 Trial design (tick √ all that apply)  
 Placebo-control  Please justify use of a placebo: 
 
 
 Phase I               Phase II            Phase III           Phase IV  
 Single centre                         National multi-centre                 International multi-centre 
 Open label/ roll-over/ extension study. (If yes, a summary of the main findings, including safety and 
efficacy data, from the previous study must be included in the appendices. This is a requirement for HREC 
review.) 
 
6.7 Is the PI free to publish the findings of this trial?  
(tick √) 
  Yes   No   





7. Statement of conflict of interest 
The PI is expected to declare any existing or potential conflict of interest that may affect the scientific 
integrity and ethical conduct of this research. For purposes of this section, ‘immediate family’ means the PI’s 
spouse or domestic partner and dependent children.  Please tick √ all that apply: 
I, or any member of my immediate family, do not have any interest related to this research 
(e.g. financial interest in the sponsor of the research or intervention being tested.) 
√ 
I, or any member of my immediate family, do not have a proprietary interest in the product 
being tested in this research (e.g. patent, trademark, copyright, licensing agreement). 
 
I, or any member of my immediate family, do not have any relationships related to this 
research (e.g. board membership, consultative, executive, employment) or any entity with an 
ownership interest in the research other than the relationship of sponsor-investigator. 
 
As Principal Investigator of this research I am aware of a potential conflict of interest. Please 
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8. Declarations and Signatures 
This application will not be processed unless all the required declarations and signatures are completed 
according to the Committee’s Standard Operating Procedures. 
8.1 Head of Department or Division 
 
My signature confirms that: 
 
i. The researcher(s)/student(s)/supervisor(s) have the skills, training, experience and time to undertake this 
research. 
ii. There are adequate resources (e.g. equipment, space, support services) to perform this research. 
Signature of Head  Date  
Print name  
 
Note: Where the PI is also Head of Department, confirmation must be obtained from an authorised designee. 
PIs may not approve their own research. 
 
8.2 Chairperson of the Departmental Research Committee (DRC)  
My signature confirms that: 
 
i. This research has undergone peer review by a person(s) experienced in the field of study. 
ii. This research is well-designed and scientifically sound. 
iii. Where relevant, all methodological issues have been resolved to the satisfaction of the peer 
reviewer(s). 
iv. If conducted according to the protocol, this research is expected to yield valid and useful findings. 
Signature of Chairperson  Date:  
Print name  
 
Note: Where the PI is also the Chairperson of the DRC, confirmation must be obtained from an authorised 
designee. PIs may not approve their own research. 
 
8.3 Student supervisor  (if research is for a degree) 
My signature confirms that: 
 
i. The student researcher has adequate training and resources to complete the research in the allocated 
timeframe. 
ii. The research has scholarly merit. 
iii. The level of risk inherent in the study is commensurate with the student researcher’s experience and 
the extent of oversight that I will provide. 
iv. I will meet the student on a regular basis to monitor progress and address any problems that may arise 
during the study. 
v. If applicable, I will ensure that the research undergoes continuing review as required by the HREC. 
vi. If applicable, I will ensure that the student researcher reports unanticipated problems or serious 
adverse events to the HREC. 
vii. I will arrange for an alternative faculty supervisor to take responsibility for this research during periods 
of absence such as sabbatical or annual leave. 
Signature of Supervisor  Date:  
Print name Prof Brian Eley 
 
Note: The supervisor and student researcher are jointly responsible for the ethical conduct of this research from 
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8.4 Principal investigator 
My signature confirms that: 
 
 
i. Information in this application is true and accurate. 
ii. I will begin the research only after HREC approval is obtained. 
iii. I accept full responsibility for the conduct of this research and the protection of participants’ rights and 
welfare. 
iv. I will conduct the research according to all ethical, regulatory and legal requirements laid down in the 
HREC’s Standard Operating Procedures. 
v. I will provide progress reports to the HREC as requested, including a final closing report at the end of 
the research. 
vi. I will notify the HREC in writing if any change to the research is proposed and await approval before 
proceeding with the proposed change except when urgently necessary to protect participants’ safety. 
vii. I will notify the HREC in writing immediately if any adverse event or unanticipated problem occurs 
during the research. 
viii. I will allow an audit of my research if requested by the HREC. 
ix. I have the time, training, experience and resources to oversee this research. 
Signature of PI  Date: 12/10/2010 
Print name David le Roux 
 
New protocol submission checklist 
Please ensure that all the applicable sections are fully completed and included in the submission. Missing 
information will delay the review process as the application will be returned to the PI. Sections A-C must be 
included. Instructions for submission of new applications are posted on the HREC website. 
Have you included? 
 
 Section A: New Protocol Application Form 
 Section B: Synopsis  
 Section C: Research Protocol  
 Appendices (as applicable): 
 Sponsor’s protocol 
 NIH or other US federal grant application (if PI is primary awardee) 
 Investigator’s brochure and package inserts 
 Surveys, questionnaires, interview schedules 
 Recruitment materials: advertisements, flyers, posters 
 Materials for participants: diaries, patient identification cards, newsletters, educational pamphlets 
 Consent and assent forms (English versions) 
 Letters of authorisation from institutions such as hospitals, clinics and schools 
 A summary of Phase III efficacy and safety data if this is an application for an open label or 
extension of a previously approved study 
 Budget summary 
 MCC letter of approval, if available 
 If an application has been submitted to the MCC, a copy of Section 13 (Ethical Issues) extracted 
from the CTF1 application form  
 In the case of clinical trials, PI’s declaration, CVs and GCP certificates for PI and co-investigators 
 Other relevant documentation 
 
Please submit the completed 
protocol together with an 
electronic copy to: 
 
Mrs Lamees Emjedi 
 
Research Ethics Committee 
E 52 Room 24, Old Main Building, Groote Schuur Hospital, 
Observatory 
Telephone:  27 21 406 6338 
Fax:    27 21 406 6411 













10 November 2010 
HREC REF: 511/2010 
Dr D Le Roux 
Paediatric Infectious DISeases Unit 
Paediatric 
Red Cross 
Dear Dr Le Roux 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021J 406 6626 • Facsimile [021J 406 6411 
e-mail: 
PROJECT TITLE: IMPACT OF MEASLES EPIDEMIC AT RED CROSS CHILDREN'S HOSPITAL, 2009-2010: A 
RETROSPECTIVE RECORD REVIEW 
Thank you for submitting your new study to the Faculty of Health Sciences Human Research Ethics Committee 
It IS a pleasure to inform you that the FHS HREC has formally approved the above mentioned study. 
Approval is granted for one year until 15 November 2011. 
Please send us an annual progress report (website form FHS 016) if your research continues beyond the approval 
period. Alternatively, please send us a brief summary of your findings so that we can close the research file. 
Please note that the ongoing ethical conduct of the study remainS the responsibility of the principal investigator 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN 
CHAIRPERSON, HSF HUMAN ETHICS 
Federal Wide Assurance Number: FWA00001637. 











UNIVERSITY OF CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
Human Research Ethics Comm ittee 
FHS017: Annual progress and study closure report 
Record Reviews/Audits/Collection of Biological Specimens/Repositories/Databases/Registries 
1. Protocol information 
Date 30 December 2011 
HREC REF Number HREC REF 51 112010 
Protocol number (if Impact of measles epidemic at Red ero i!<.~g~ffd.f ;::.u~ , ","" '") 1\ ,1\. a 
applicable) & Protocol retrospective record review "EffiTCS COMMmEE 
title 
Principal Investigator David Ie Raux 2012 -01- 0 6 .. 
Department / Office Dept Paediatrics and Child Health, Red Cross thill:lleAUH>~fENCES FACULTY 
Internal Mail Address 
David.leRoux@uct.ac.za UNNERSITY OF CAPE TOWN 
1.1 Does this protocol receive US Federal funding? 10 Yes 1 )~No -
2. Protocol status (tick ,,) 
0 Research-related activities are ongoing 
[Y Data collection is complete, data analysis only 
0 All research-related activities are complete (i.e. final report) 
3. Protocol summary 
Total number of records or specimens collected, reviewed or stored since the original 1859 
approval 
Total number of records or specimens collected . reviewed or stored since last progress N /A 
Have any research-related outputs (e.g. publications. abstracts, conference 
presentations) resulted from this research? r s Poster presented at FIDSSA 
If yes. please list and attach with this report. conference. Durban. September 
on11 
My signature certifies that I will maintain the anonymity and/ or confidentiality of information collected in this 
research. If at any time I want to share or re-use the information for purposes other than those disclosed in 
the original approval , I will seek further approval from the HREC. 
Signature of PI 
Signature of Supervisor 
(if PI is a student) 















UNIVERSITY OF CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
Human Research Ethics Committee 
- ... 
HREC office use only (FWA00001637; IRBOOOO1938) 
This serves as notification of annual or final approval, including any documentation described above. 
·~pproved Annual progress report 
OR 0 Approved Study closure report 




Chairperson of the HREC 
15 June 2010 
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Dr David Martin le Roux     MPhil(Paediatric Infectious Diseases) 
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Material submitted for publication in the South African Medical Journal (SAMJ) is accepted provided 
it has not been published elsewhere. The SAMJ reserves copyright of the material published. 
 
The SAMJ does not hold itself responsible for statements made by the authors. 
 
AUTHORSHIP 
All named authors must give consent to publication. Authorship should be based only on substantial 
contribution to: (i) conception, design, analysis and interpretation of data; (ii) drafting the article or 
revising it critically for important intellectual content; (iii) final approval of the version to be 
published. All three of these conditions must be met (Uniform requirements for manuscripts 
submitted to biomedical journals; www.icmje.org/index.html). 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
Evidence must be provided of Research Ethics Committee approval of the research where 
relevant. 
 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with the 
product or subject that may constitute conflict of interest. 
 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
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Measles vaccination has been very effective in reducing the global 
measles disease burden. However, outbreaks can occur when 
inadequate vaccination coverage allows accumulation of a sufficient 
number of susceptible individuals in a population. The estimated 
level of population immunity needed to prevent measles outbreaks is 
about 95%.1 South Africa introduced routine measles vaccination in 
1975, and measles became a notifiable condition in 1979. In 1995, the 
current 2-dose strategy (routine vaccination at 9 and 18 months) was 
adopted. Case-based surveillance was introduced in 1998, with all 
suspected cases having blood or urine tested at the National Institute 
of Communicable Diseases (NICD).2
Accurate coverage of measles vaccination has been difficult to 
determine. In 2009, the South African Department of Health (DoH) 
South African measles outbreak 2009 - 2010  
as experienced by a paedi tric hospital
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Introduction. Between 2009 and 2010, South Africa experienced a 
major measles outbreak, with more than 18 000 confirmed cases 
reported to the National Institute of Communicable Diseases. 
Methods. We studied measles admissions during the outbreak 
to Red Cross War Memorial Children’s Hospital, Cape Town, 
between 1 November 2009 and 31 July 2010. Factors associated with 
mortality were retrospectively identified from notification records 
and hospital admissions data. Multivariate logistic regression was 
used to investigate potential risk factors for death.
Results. In total, 1 861 children were diagnosed with measles; 
552 (30%) were admitted to hospital. The most common reason 
for admission was pneumonia (379 (68%)) and/or diarrhoea 
(262 (48%)). The median age at admission was 7.36 months 
(interquartile range (IQR) 5.0 - 10.7). The median duration of 
admission was 4 days (IQR 2 - 6); total hospital admission time was 
3 746 days (10.3 child-years). HIV status was known in 404 (73%) 
children: 39/400 (14%) were HIV-infected.  Eighteen children died 
(3% of all admissions); 15 (83%) of them were less than 1 year old. 
In the regression model, HIV-infection (adjusted odds ratio (aOR) 
7.55, 95% confidence interval (CI) 2.27 - 25.12) and female sex 
(aOR 3.86, 95% CI 1.26 - 11.84) were associated with higher odds 
of death.
Conclusions. There was a large paediatric admission burden 
during the 2009 - 2010 measles outbreak in Cape Town; young 
children were predominantly affected. HIV-infected children had a 
significantly higher case fatality.
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estimated national coverage with routine measles vaccine to be 99%, 
but the World Health Organization (WHO) and United Nations 
Children’s Fund (UNICEF) coverage estimates were only 65%.3 In 
2004, a survey in Western Cape Province found 79% of children to 
be ‘fully vaccinated’.4 In 2005, another study estimated that 93% of 
children had received the first dose of measles vaccine, but only 60% 
a second dose.5 The authors concluded that routine coverage in the 
Western Cape was too low to prevent a measles outbreak.
The last major outbreak in South Africa occurred in 1992. In July 
2009, a cluster of measles cases was detected in Tshwane; in August, 
the outbreak spread to Johannesburg, and then rapidly throughout 
the rest of the country. The first case in the Western Cape was 
confirmed in September 2009; there were 14 cases in October, and 
by November the outbreak was well established throughout the 
Cape Town metropole.6 We report the epidemiology of measles cases 
presenting to a single paediatric hospital in Cape Town.
Methods
Red Cross War Memorial Children’s Hospital (RXH) is a 290-bed, 
level 3 academic hospital in Cape Town. During the outbreak, 
children with measles who needed admission were stabilised and 
admitted to the ‘short stay ward’, from which they were either 
discharged home, transferred to another hospital (mild disease), or 
admitted to the medical wards or Intensive Care Unit (ICU) at RXH 
(severe disease or other significant co-morbid disease).
All children diagnosed with measles at RXH between 1 November 
2009 and 31 July 2010 were retrospectively identified from paper 
notification records, electronic hospital admission records, and the 
ICU database. Folders were reviewed and patients meeting the WHO 
clinical case definition were included.7 Suspected measles cases that 
tested negative for measles IgM antibodies were excluded. Data were 
captured onto a paper form and entered into an electronic database. 
Final discharge dates and re-admission dates were extracted from the 
city-wide hospital admission computer system; this includeD all the 
time spent in any hospital in the city.
All children were managed according to written hospital protocols. 
In-patient management of pneumonia included intravenous 
ampicillin, gentamicin and cloxacillin. Vitamin A was dosed 
according to WHO guidelines.7 During the outbreak, all children 
attending RXH who did not have clinical measles were given 
measles prophylaxis. Children older than 6 months were given 
a single dose of intramuscular measles vaccine (Rouvax, Sanofi 
Pasteur, France); children under 6 months and children with severe 
immunosuppression were given an intramuscular dose of human 
immunoglobulin (Intragam, National Bioproducts Institute, South 
Africa), according to the manufacturer’s instructions.
HIV testing was performed when deemed clinically appropriate 
by the treating clinicians. Children >18 months old were 
considered HIV-infected if HIV antibodies were detected by 
enzyme-linked immunosorbent assay (ELISA) testing. Results 
were confirmed on a second specimen with a manual ELISA 
(Enzygnost Anti-HIV 1/2 Plus, Siemens Healthcare Diagnostic 
Products GmbH, Marburg, Germany). Children <18 months 
old were considered HIV-infected with positive HIV DNA PCR 
(Cobas Ampliprep system, Roche Molecular Systems, Branchburg, 
New Jersey, USA). Positive HIV DNA PCR results were confirmed 
with HIV viral load testing.
For summary statistics, categorical data are expressed as number 
(percentage); continuous data are expressed as median (inter-quartile 
range (IQR)). Median values were compared with the Wilcoxon 
rank-sum test. Risk ratios were calculated to compare the proportion 
of children who died or were re-admitted by gender and HIV status.
Factors associated with death were explored with multivariable 
logistic regression. We evaluated the influence of age, sex, HIV status, 
immunisation status, evidence of vitamin A administration, the 
presence of a ‘Road to Health Card’ and the weight-for-age Z-score 
(calculated from growth charts from the Centers for Disease Control 
and Prevention (CDC)). Weight-for-age Z-score of less than -2 was 
considered ‘moderate underweight for age’; and less than -3 was 
considered ‘severe underweight for age’. Variables associated with the 
outcome at the α=0.1 level were included for multivariable analysis. 
Automated backwards and forwards step-wise model building 
procedures were used; potential models were compared with Akaike’s 
Information Criteria (AIC). Collinearity was assessed with variance 
inflation factors. The final model chosen was most parsimonious 
and presented the best AIC value. A sensitivity analysis was done 
to examine the influence of the children with unknown HIV status. 
Analyses were done in Stata version 10 (Statacorp, College Station, 
Texas, USA). All p-values are two-tailed (α=0.05).
Ethics approval was obtained from the Department of Paediatrics 
and Child Health Departmental Research Committee and the 
University of Cape Town Human Research Ethics Committee, 
HREC-REF number 511/2010.
Results
From 1 November 2009 to 31 July 2010, 1 861 children with measles 
presented to RXH, who have been categorised as follows.
Outpatients
In total, 1 309 (70%) children were treated as outpatients; most 
presented in March and April 2010 (Fig. 1). The median age was 
8.9 months (IQR 6.1 - 30.4) (Table 1). Documentation of measles 
vaccination status in the hospital notes was poor: of the 565 
children eligible for routine measles vaccination, only 270 (48%) 
had vaccination status recorded, and only 68% had vitamin A 
administration documented in the hospital notes (Table 1).
Admissions
There were 552 hospital admissions; inpatients were significantly 
younger than children treated only as outpatients (median age 7.4 
months v. 8.9 months, Wilcoxon p<0.0001) (Table 1). Most children 
(357/552 (65%)) were younger than 9 months (the age of routine 
measles vaccination) (Fig. 2). At least 379 (63%) children presented 
with pneumonia, 262 (47%) with severe diarrhoea and 163 (30%) 
with both. Other reasons for admission included croup (37 (7%)), 
and suspected meningitis (2 (0.4%)). Vaccination status was recorded 
in the hospital notes in 92/195 (47%) children older than 9 months; 
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only 40/92 (45%) had had any measles vaccine documented in 
the hospital notes (Fig. 2). During the study period, venous blood 
for serological testing was sent from 102 children admitted with 
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suspected measles; 96 (17%) had detectable measles IgM antibodies; 
4 specimens were invalid or insufficient. Only 2 children with 
clinically-suspected measles were confirmed measles IgM negative; 
both children had detectable rubella IgM antibodies, and were 
excluded from this analysis.
Of the admitted children, 404 (73%) had known HIV status: 
39/404 (10%) were HIV-infected, of whom 20/39 (51%) had been 
on antiretroviral therapy (ART) for more than 3 months. All HIV-
infected children with severe measles subsequently commenced 
ART. Only 3/23 (14%) HIV-infected, vaccine-eligible children had 
documentation of any measles vaccination.
Deaths and complications
Of all admissions, 18 (3%) children died, of whom 13 (72%) were less 
than 1 year old; 11 (61%) deaths were due to respiratory failure; other 
causes included septic shock with multi-organ failure (4 children (22%)) 
and cerebral ischaemia after cardio-respiratory arrest (2 children (11%)). 
One child died from massive bowel ischaemia and necrosis.
Of HIV-infected children 7/39 (18%) died v. 11/365 (3%) known 
HIV-uninfected children. Case fatality was 5% among girls v. 1.7% 
of boys (Table 2). In multivariable logistic regression adjusted for 
age and weight-for-age, HIV infection and gender remained strong 
predictors of mortality (Table 3). Of HIV-infected children who died, 
2/7 (29%) had received ART for at least 3 months.
During the study period, 4 children with complications of measles 
required tracheostomies (Sr Jane Booth, personal communication). 
One child was referred with severe croup; 3 children developed upper 
airway damage following prolonged intubation and ventilation for severe 
pneumonia. All 4 entered the RXH home tracheostomy programme and 
were discharged home within 2 months of their admission but had recurrent 
re-admissions with respiratory infections. By March 2012, 3 children had 
been successfully decannulated, and one remains with a tracheostomy.
Length of stay and re-admissions
The median duration of admission was 4 days (IQR 2 - 6 days). HIV-
infected children were admitted for longer (median 6 days, IQR 4 - 14 
days) than HIV-uninfected children (median 3 days, IQR 2 - 5 days; 
Wilcoxon p=0.0007).
Among survivors, 53/287 (18%) of boys were re-admitted v. 
19/247 (8%) of girls (risk ratio (RR) for re-admission 2.40 (95% CI 
1.46 - 3.94, p=0.0003)). Moderate or severe underweight for age 
(weight for age Z-score less than -2) was also strongly associated 
with readmission: of 531 surviving children with known weight-for-
age, 26/113 (23%) who were moderately or severely underweight 
for age were re-admitted v. 46/418 (11%) of children who were not 
underweight for age, RR 2.09 (95% CI 1.36 - 3.23, p=0.0009). Of 
HIV-infected children, 28% (9/32) were re-admitted v. 12% (44/354) 
HIV-uninfected children (RR 2.26, 95% CI 1.22 - 4.20, p=0.01).
Total primary hospital admission time was 3 746 days (10.3 child-
years). Of the 534 surviving children, 72 (13%) were re-admitted 
within 90 days; 24 of these children (24/534 (4% of all the survivors)) 
were re-admitted a third time within 90 days of their first admission. 
The total time spent in hospital, including the primary admission and 
subsequent re-admissions within 3 months of discharge, was 4 477 
days (12.3 child-years). This constitutes 6.6% of total in-patient days 
at RXH during the study period.
Discussion
Between April 2009 and November 2010, South Africa experienced 
a national measles outbreak, with 18 311 serologically confirmed 
measles cases. Almost a quarter of these cases were infants younger 
than 9 months.8 The magnitude was probably even greater, as many 
cases were diagnosed clinically: in our institution, only 96/552 (17%) 
measles admissions were laboratory confirmed.
At RXH, the main burden of disease, in terms of hospitalisations 
and mortality, was in infants <1 year old. There was an especially high 
burden in infants younger than 6 months. There are several reasons 
why the very young were so severely affected. Children become 
susceptible to measles infection once maternally-derived transplacental 
antibody levels are below a protective threshold. Vaccinated women 
transfer fewer antibodies than mothers whose immunity followed 
wild-type measles infection. In Belgium, babies of vaccinated women 
received a third of measles-specific antibodies v. babies born to women 
with immunity owing to natural measles infection.9 The antibodies are 
also lost more quickly: the median time to loss of immunity was 0.97 
months for babies born to vaccinated women v. 3.78 months for babies 
born to women with previous measles infection.9
In Cape Town, there has been little circulating measles virus 
since the 1992 outbreak; most women of childbearing age have 
not had natural measles infection. Since its inception in 1975, the 
coverage of the measles immunisation programme has been too low; 
many women have never been vaccinated. Their babies received no 
measles-specific antibodies, rendering them susceptible to measles 
infection from a very young age.
Case fatality of measles can range from 0.1% in developed 
countries to 30% in outbreaks among refugee populations. The 
incidence is influenced by age, intensity of exposure to measles virus, 
nutritional status, vaccination status, immune deficiency, vitamin A 
administration, and access to appropriate case management.10 During 
the outbreak under review, case fatality among inpatients at RXH was 
3% (18 deaths out of 552 admissions). Low weight-for-age Z-score 
was strongly associated with increased mortality, with 35% increased 
odds of death for every standard deviation below the expected weight 
for age. Furthermore, among survivors, low weight for age Z-score 
doubled the risk of re-admission. The finding of similar measles 
incidence among boys and girls, but with increased mortality among 
Table 3. Odds ratios (unadjusted and adjusted) of death
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p value
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girls, has previously been described,11 but the biological mechanism 
is not well understood.
We observed increased case fatality among inpatients with HIV-
infection. They had an 18% case fatality ratio, and 7 times higher 
odds of death than HIV-uninfected children, despite half of them 
being established on ART. This figure is higher than previously 
reported in areas with high HIV prevalence. In the 2003 - 2005 
measles outbreak in Johannesburg, 14% of known HIV-infected 
children died; they had a 3.3 times higher risk of death than HIV-
uninfected children.12 In a 6-year study in Zambia, case fatality 
among HIV-infected children was 12%, with 2.5 times higher odds 
of death than HIV-uninfected children.13 Our  higher case fatality 
may reflect a selection bias for disease severity, as children admitted 
to RXH had more severe disease than children treated as outpatients 
or in other facilities in the city.
For several reasons, HIV-infected children have a more severe 
clinical course than HIV-uninfected children. HIV-infected children 
have deficient cellular and humoral immunity and impaired innate 
immune responses.14 Despite commencing ART, HIV-infected children 
had twice the risk of re-admission v. HIV-uninfected children, which 
may reflect the combined immune-suppressive effect of acute measles 
infection in an already-compromised individual. HIV-infected children 
have suboptimal responses to measles vaccination. Vaccination, even if 
not fully protective against measles infection, can attenuate severity of 
disease.10 In HIV-uninfected children, response to measles vaccination 
is age-dependent, with better antibody responses in older children. 
At 9 months, about 90% will develop protective antibody levels 
(interquartile range 82 - 95%); at 12 months, 99% will develop 
protective levels after a single dose of measles vaccine, (interquartile 
range 93 - 100%).7 However, the response in HIV-infected children 
to vaccination does not improve with age. A meta-analysis of 26 
studies of vaccine responses in HIV-infected children at different ages 
showed highly variable responses, but no trend towards improved 
seroconversion among older children. The efficacy of a single dose 
of measles vaccine, whether given at 6, 9 or 12 months, was about 
59% (95% CI 46 - 71%).15 These studies only reported attainment 
of protective antibody levels, and did not take into account T-cell 
mediated immunity, effectiveness of protection from clinical disease, 
or the effect of commencing ART. However, in a retrospective analysis 
of the 2003 - 2005 measles outbreak in Johannesburg, effectiveness of 
measles vaccine in preventing clinical disease among HIV-infected 
children was calculated at 63%.12 Infants born to HIV-infected mothers 
who are themselves uninfected (HIV-exposed but uninfected) also 
have increased susceptibility to measles infection. HIV-exposed infants 
have lower levels of maternal antibody, and protective antibody is lost 
earlier than in HIV unexposed infants.16
Among the children admitted to hospital, there were 69 possible 
‘vaccine failures’ – children with a record of at least 1 dose of measles 
vaccine, who developed severe clinical disease requiring admission. 
There are several possible explanations for these vaccine failures. When 
vaccinations were documented, the admitting clinician noted whether 
measles vaccine had been given, but not the date of administration. It 
was not possible to determine retrospectively the age at vaccination or 
time from vaccination till clinical disease. All children >6 months old 
received measles vaccine if they attended hospital, and there were 2 
nationwide mass vaccination campaigns (12 - 23 April and 24 - 28 May 
2010). However, vaccination of young children is less effective than of 
children >1 year old.7 Some children might already have been infected 
with measles, but were vaccinated while in the incubation period. 
All children <6 months old seen at the hospital who did not have 
measles were given measles immune globulin. If these children were 
subsequently vaccinated, the immune globulin could impair vaccine 
effectiveness for up to 9 months.17 If they developed clinical measles 
despite having had a vaccine dose recorded in their Road to Health 
Card, they would be considered vaccine failures.
This study has several limitations. The data were captured 
retrospectively from clinical case notes, much data had not been 
recorded, vaccine status was very poorly recorded, and we were not 
able to explore many of the possible vaccine failures. Weight-for-
height is a better marker of malnutrition than weight-for-age, but 
few children had their height measured. Some children with low 
weight-for-age Z-scores might have been born pre-term, which might 
be a marker of low birthweight or pre-term delivery, not adequacy of 
post-natal nutrition. Most of the clinically diagnosed cases were not 
laboratory-confirmed. Dermatologists reviewing children admitted 
with severe measles at another hospital in Cape Town during the 
epidemic found a high correlation between clinically-suspected 
measles and laboratory-confirmed measles. However, this might not 
apply to clinical diagnosis of mild disease in outpatients.18
Conclusion
The 2009 - 2010 measles outbreak was associated with a large 
case-load, and high morbidity and mortality at RXH; >65% of 
the admissions were for children aged <9 months. Measles is a 
preventable disease, given sufficient political will for the interruption 
of measles transmission. Vaccine coverage must urgently be 
improved and supplementary immunisation activities to under-
serviced communities be targeted. HIV-infected children had 
significantly higher case fatality and risk of re-admission. Prevention 
of vertical transmission of HIV is a national priority, coverage of 
these programmes must be extended, and early infant HIV diagnosis 
and treatment should be improved.
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